Cart
sales@molnova.com
Plonmarlimab
CAS No. 2377482-36-3
Plonmarlimab( —— )
Catalog No. M36822 CAS No. 2377482-36-3
Plonmarlimab (TJ003234) is an anti-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody with potential antiviral activity for the study of immune diseases and novel coronavirus infections.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 453 | Get Quote |
|
| 5MG | 687 | Get Quote |
|
| 10MG | 937 | Get Quote |
|
| 25MG | 1371 | Get Quote |
|
| 50MG | 1812 | Get Quote |
|
| 100MG | 2421 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePlonmarlimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionPlonmarlimab (TJ003234) is an anti-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody with potential antiviral activity for the study of immune diseases and novel coronavirus infections.
-
DescriptionPlonmarlimab (TJ003234) is an anti-GM-CSF monoclonal antibody. Plonmarlimab can be used for research of rheumatoid arthritis and COVID-19.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetCSF1R
-
Recptorc-Fms | SARS-CoV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2377482-36-3
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bonaventura A, et al. Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. Front Immunol. 2020 Jul 3;11:1625. ?
molnova catalog
related products
-
c-Fms-IN-13
c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor (IC50 = 17 nM) and serves as an anti-inflammatory agent.
-
PLX647
PLX647 is a highly specific dual FMS/KIT kinase inhibitor with IC50 of 28/16 nM respectively.
-
JNJ-28312141
JNJ-28312141 is a potent, orally active CSF-1 receptor (CSF-1R) kinase inhibitor with IC50 of 0.69 nM.
